Antiplatelet Therapy in Patients with End-Stage Renal Disease

Introduction to Antiplatelet Therapy

• For patients with end-stage renal disease (ESRD) on dialysis requiring single antiplatelet therapy, low-dose aspirin (75-100 mg daily) is recommended for secondary prevention of cardiovascular events, while clopidogrel 75 mg daily is the preferred alternative in cases of aspirin intolerance or contraindication, as supported by the American Heart Association and the American College of Chest Physicians 1, 2
• A meta-analysis of trials showed increased risk of both major and minor bleeding without significant reduction in cardiovascular events when using aspirin for primary prevention in CKD, highlighting the need for careful consideration of antiplatelet therapy in this population, with a strength of evidence Grade 1C 1

Dosing and Administration

• No dose adjustment is required for aspirin or clopidogrel in ESRD patients on dialysis, with a recommended dose of 75-100 mg daily for aspirin and 75 mg daily for clopidogrel, as recommended by the American Heart Association and the National Kidney Foundation's K/DOQI guidelines 2, 3
• The American Heart Association recommends using the lowest effective dose of antiplatelet agent to minimize bleeding risk in patients with ESRD on dialysis, with a strength of evidence Grade 1B 2

Special Considerations

• Dialysis patients have inherently higher bleeding risk due to uremic platelet dysfunction, frequent vascular access procedures, heparin exposure during dialysis, and comorbidities such as hypertension and diabetes, as reported by the National Kidney Foundation's K/DOQI guidelines and the American Journal of Kidney Diseases 1, 3
• The National Kidney Foundation's K/DOQI guidelines emphasize that dialysis patients with acute coronary syndrome should receive the same treatments as the general population, including antiplatelet therapy, with attention to drugs requiring dosage adjustment, with a strength of evidence Grade 1C 3

Management of Bleeding Risk

• Regular monitoring for bleeding complications, especially gastrointestinal bleeding, is recommended for patients with ESRD on dialysis and antiplatelet therapy, as recommended by the American College of Chest Physicians and the American Journal of Kidney Diseases 4, 5
• Consideration of gastroprotection with proton pump inhibitors is recommended for high-risk patients, such as those with a history of gastrointestinal bleeding or concomitant use of other medications that increase bleeding risk, as recommended by the American College of Chest Physicians and the European Society of Cardiology 4, 6, 7

Transition from Dual to Single Antiplatelet Therapy

• After 12 months of dual antiplatelet therapy, transition to single antiplatelet therapy is recommended (Grade 1B) for patients with acute coronary syndrome or coronary stent placement, according to the American College of Chest Physicians and the American College of Cardiology 4
• Single antiplatelet therapy should be continued indefinitely for secondary prevention in patients with ESRD on dialysis, as recommended by the American College of Cardiology and the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines 4, 8
• Aspirin is not recommended for primary prevention of cardiovascular events in patients with kidney disease, including those on dialysis, due to the potential for bleeding risk to equal or outweigh uncertain cardiovascular benefits, as stated by the American Journal of Kidney Diseases and supported by the KDIGO guidelines and the American College of Cardiology 1, 8, 6

Secondary Prevention

• Aspirin is recommended for secondary prevention in patients with kidney disease, including those on dialysis, who have established cardiovascular disease, particularly following myocardial infarction, as stated by the American Journal of Kidney Diseases and supported by the KDIGO guidelines (Grade 1C) 3, 6
• Patients with kidney disease who received aspirin following myocardial infarction had a 43% lower odds of dying within 30 days, according to the American Journal of Kidney Diseases 3
• Multiple guidelines, including NICE, KDIGO, and ACC/AHA/ASA, consistently support aspirin for secondary prevention in patients with kidney disease and established cardiovascular disease 8

Primary Prevention

• For primary prevention cases, individual risk factors should be assessed, and aspirin considered on a case-by-case basis for those with very high cardiovascular risk and low bleeding risk, as per general clinical guidelines 8
• The lowest effective dose of aspirin (75-100 mg daily) should be used if indicated for secondary prevention, as recommended by the European Society of Cardiology 7
• The KDIGO guidelines suggest considering P2Y12 inhibitors as alternative antiplatelet agents when there is aspirin intolerance 6